Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 1, 2017, Pages

  Robertson, Lindsay ^a   Atallah, Edmond ^b   Stansby, Gerard ^a  

^a FREEMAN HOSPITAL   (United Kingdom)

^b UNITED LINCOLNSHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; METOPROLOL; CARDIOVASCULAR AGENT;

ABDOMINAL AORTA ANEURYSM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DRUG EFFICACY; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SIDE EFFECT; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COMPLICATION;

ANTIHYPERTENSIVE AGENTS; AORTIC ANEURYSM, ABDOMINAL; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; HUMANS; METOPROLOL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84903753633     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010447.pub3     Document Type: Review

References (79)

1. Yang H, Raymer K, Butler R, Parlow J, Roberts R. The effects of perioperative β-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. American Heart Journal 2006;152(5):983-90. [3415576]
2. Yang H, Raymer K, Butler R, Parlow J, Roberts R, Tech M. Metoprolol after vascular surgery. Canadian Journal of Anaesthesia 2004;51(Suppl 1):A7. [3415575]
3. Ashes C, Judelman S, Wijeysundera DN, Tait G, Mazer CD, Hare GM, et al. Selective ß1-antagonism with bisoprolol is associated with fewer postoperative strokes than atenolol or metoprolol: a single-center cohort study of 44, 092 consecutive patients. Anesthesiology 2013;119(4):777-87. [4504946]
4. Berwanger O, Soares RM, Ikeoka DT, Paisani DM, Silva BG, Bernardez-Pereira S, et al. Atorvastatin for the prevention of major vascular events in patients undergoing non-cardiac surgery: the load-pilot randomized clinical trial. Circulation 2015;132:A13635. [4504948]
5. Cesanek P, Schwann N, Wilson E, Urffer S, Maksimik C, Nabhan S, et al. The effect of beta-blocker dosing strategy on regulation of perioperative heart rate and clinical outcomes in patients undergoing vascular surgery: a randomized comparison. Annals of Vascular Surgery 2008;22(5):643-8. [3415578]
6. Bakker EJ, Ravensbergen NJ, Voute MT, Hoeks SE, Chonchol M, Klimek M, et al. A randomised study of perioperative esmolol infusion for haemodynamic stability during major vascular surgery: Rationale and design of DECREASE-XIII. European Journal of Vascular and Endovascular Surgery 2011;42(3):317-23. [3415580]
7. Dunkelgrun M, Boersma E, Koopman-Van Gemert AWMM, Van Poorten F, Kalkman C, Schouten O, et al. Fluvastatin and bisoprolol for cardiac risk reduction in intermediate-risk patients undergoing non-cardiovascular surgery: a randomised controlled trial. European Heart Journal 2008;29(Abstract Suppl):602-3. [3415581]
8. Dunkelgrun M, Boersma E, Schouten O. Koopman-Van Gemert AWMM, Van Poorten F, Bax JJ, et al. for the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate-risk patients undergoing noncardiovascular surgery: a randomised controlled trial (DECREASE-IV). Annals of Surgery 2009;249(6):921-6. [3415582]
9. Flu WJ, van Kujik JP, Chonchol M, Winkel TA, Verhagen HJ, Bax JJ, et al. Timing of perioperative Beta-blocker treatment in vascular surgery patients: influence on post-operative outcome. Journal of the American College of Cardiology 2010;56(23):1922-9. [3415583]
10. Hoeks SE, Schouten O, Dunkelgrun M, Van Lier F, Durazzo AE, Neskovich AN, et al. Perioperative stroke in non-cardiac surgery; the impact of prophylactic beta-blocker therapy. European Heart Journal 2008;29(Abstract Supplement):395. [3415584]
11. Poldermans D, Bax JJ, Schouten O, Neskovic AN, Paelinck B, Rocci G, et al. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo Study Group. Should major vascular surgery be delayed because of preoperative cardiac testing in intermediate-risk patients receiving beta-blocker therapy with tight heart rate control?. Journal of the American College of Cardiology 2006;48(5):964-9. [3415585]
12. Poldermans D, Boersma E, Bax JJ, Leendertse-Verloop K, Poldermans VC, Yo TI, et al. With bisoprolol fewer perioperative cardiac complications in high-risk patients undergoing major vascular surgery. Nederlands Tijdschrift voor Geneeskunde 2000;144(42):2011-4. [3415586]
13. Poldermans D, Boersma E, Bax JJ, Thomson IR, Paelinck B, Van de Ven LL, et al. Bisprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. European Heart Journal 2001;22(15):1353-8. [3415587]
14. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. New England Journal of Medicine 1999;341(24):1789-94. [3415588]
15. Poldermans D, Shelton M. Fluvastatin XL use is associated with improved cardiac outcome after major vascular surgery. Results from a randomised placebo controlled trial: DECREASE III. https://www.escardio.org/The-ESC/Press-Office/Press-releases/Fluvastatin-XL-Use-is-Associated-With-Improved-Cardiac-Outcome-After-Major-Vascu 2008 (accessed 5 January 2017). [3415589]
16. Schouten O, Boersma E, Hoeks SE, Benner R, van Urk H, Van Sambeek MR, et al. for the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Fluvastatin and perioperative events in patients undergoing vascular surgery. New England Journal of Medicine 2009;361(10):980-9. [3415590]
17. Schouten O, Hoeks SE, Voute MT, Boersma E, Verhagen HJ, Poldermans D. Long-term benefit of perioperative statin use in patients undergoing vascular surgery: results from the DECREASE III trial. Journal of Vascular Surgery 2011;53(6):20S-1S. [3415591]
18. Schouten O, Poldermans D, Visser L, Kertai MD, Klein J, van Urk H, et al. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IX study. American Heart Journal 2004;148(6):1047-52. [3415592]
19. Caramelli B, Durazzo A, Ikeoka D, De Bernoche C, Monachini M, Puech LP, et al. Short-term treatment with atorvastatin for prevention of cardiac complications after vascular surgery. Abstract No 086. Atherosclerosis Supplements 2002;3:83. [3415594]
20. Durazzo AE, Machado FS, Ikeoka D, Puech LP, Caramelli B. Effect of atorvastatin on cardiovascular events after vascular surgery. Circulation 2002;106(II):343. [3415595]
21. Durazzo AE, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomised trial. Journal of Vascular Surgery 2004;39(5):967-75. [3415596]
22. Kouvelos G, Milionis H, Arnaoutoglou E. The effect of intensified lipid lowering therapy on one-year prognosis in patients undergoing vascular surgery. Interactive Cardiovascular and Thoracic Surgery 2011;12:S61-2. [4504950]
23. Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, Kostara C, Gartzonika C, Bairaktari ET, et al. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. Journal of Cardiovascular Pharmacology and Therapeutics 2013;18(1):5-12. [3415598]
24. Kouvelos GN, Arnaoutoglou EM, Milionis HJ, Raikou VD, Papa N, Matsagkas MI. The effect of adding ezetimibe to rosuvastatin on renal function in patients undergoing elective vascular surgery. Angiology 2015;66(2):128-35. [4504951]
25. Mackey WC, Fleisher LA, Haider S, Sheikh S, Cappalleri JC, Lee WC, et al. Perioperative myocardial ischemic injury in high-risk vascular surgery patients: incidence and clinical significance in a prospective clinical trial. Journal of Vascular Surgery 2006;43(3):533-8. [3415600]
26. Mangano DT, Layug EL, Wallace A, Tateo I, for the Multicentre Study of Perioperative Ischemia Research Group. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. New England Journal of Medicine 1996;335(23):1713-20. [3415602]
27. NCT01225094 Curcumin to prevent complications after elective abdominal aortic aneurysm (AAA) repair. clinicaltrials.gov/ct2/show/NCT01225094 (first received 19 October 2010). [4504953]
28. Neilipovitz DT, Bryson GL, Taljaard M. STAR VaS--Short term atorvastatin regime for vasculopathic subjects: a randomized placebo-controlled trial evaluating perioperative atorvastatin therapy in noncardiac surgery. Canadian Journal of Anaesthesia 2012;59(6):527-37. [3415604]
29. Brady AR, Gibbs JS, Greenhalgh RM, Powell JT, Sydes MR, POBBLE trial investigators. Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. Journal of Vascular Surgery 2005;41(4):602-9. [3415606]
30. Schouten O, van Urk H, Feringa HH, Bax JJ, Poldermans D. Regarding "Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial" [comment]. Journal of Vascular Surgery 2005;42(4):825, author reply 826. [3415607]
31. Devereaux PJ The perioperative ischemic evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery. Clinical Research in Cardiology 2008;97(1):8. [3415609]
32. POISE Trial Investigators: Devereaux PJ, Yang H, Guyatt GH, Leslie K, Villar JC, Monteri VM, et al. Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery. American Heart Journal 2006;152(2):223-30. [3415610]
33. POISE study group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371(9627):1839-47. [3415611]
34. Qu Y, Wei L, Zhang H. Inhibition of inflammation mediates the protective effect of atorvastatin reload in patients with coronary artery disease undergoing noncardiac emergency surgery. Coronary Artery Disease 2014;25(8):678-84. [4504955]
35. Schouten O, Hoeks SE, Boersma H. Long-term outcome of the DECREASE III trial; the impact of initiation of statin therapy prior to surgery. European Heart Journal 2011;32:332-3. [4504957]
36. Xia J, Qu Y, Shen H, Liu X. Patients with stable coronary artery disease receiving chronic statin treatment who are undergoing noncardiac emergency surgery benefit from acute atorvastatin reload. Cardiology 2014;128(3):285-92. [4504959]
37. Xia J, Qu Y, Yin C, Xu D. Preoperative rosuvastatin protects patients with coronary artery disease undergoing noncardiac surgery. Cardiology 2015;131(1):30-7. [4504961]
38. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490-4.
39. Badger SA, O'Donnell ME, Sharif MA, McMaster C, Young IS, Soong CV. The role of smoking in abdominal aortic aneurysm development. Angiology 2009;60(1):115-9.
40. Badger S, Bedenis R, Blair PH, Ellis P, Kee F, Harkin DW. Endovascular treatment for ruptured abdominal aortic aneurysm. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD005261.pub3]
41. Blanchard JF, Armenian HK, Friesen PP. Risk factors for abdominal aortic aneurysm: results of a case-control study. American Journal of Epidemiology 2000;151(6):575-83.
42. Bolsin S, Colson M, Marsiglio A. Perioperative ß-blockade. BMJ 2013;347:f5640.
43. Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Annals of Surgery 1999;230(3):289-96.
44. Brown LC, SG, Greenhalgh RM, Powell JT, Endovascular Aneurysm Repair trial participants. Incidence of cardiovascular events and death after open or endovascular repair of abdominal aortic aneurysm in the randomized EVAR trial 1. British Journal of Surgery 2011;98(7):935-42.
45. Davis M, Taylor PR. Endovascular infrarenal abdominal aortic aneurysm repair. Heart 2008;94(2):222-8.
46. de Bruin JL, Baas AF, Heymans MW, Buimer MG, Prinssen M, Grobbee DE, et al. Statin therapy is associated with improved survival after endovascular and open aneurysm repair. Journal of Vascular Surgery 2014;59(1):39-44.e1.
47. De Martino RR, Goodney PP, Nolan BW, Robinson WP, Farber A, Patel VI, et al. Optimal selection of patients for elective abdominal aortic aneurysm repair based on life expectancy. Journal of Vascular Surgery 2013;58(3):589-95.
48. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
49. Erasmus MC Follow-up Investigation Committee. Report on the 2012 follow-up investigation of possible breaches of academic integrity. 30 September 2012. http://www.erasmusmc.nl/5663/135857/3675250/3706798/Integrity_report_2012-10.pdf?lang=en (accessed 10 April 2013).
50. Filardo G, Powell JT, Martinez MA, Ballard DJ. Surgery for small asymptomatic abdominal aortic aneurysms. Cochrane Database of Systematic Reviews 2015, Issue 2. [DOI: 10.1002/14651858.CD001835.pub4]
51. GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 14 October 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
52. Greenhalgh RM, Brown LC, Kwong GP, Powell JT, SG, EVAR trial participants. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. Lancet 2004;364(9437):843-8.
53. Greenhalgh RM, Powell JT. Endovascular repair of abdominal aortic aneurysm. New England Journal of Medicine 2008;358(5):494-501.
54. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006;368(9536):659-65.
55. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
56. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and ACC/AHA Task Force on Practice Guidelines: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113(11):e463-e654.
57. Kertai MD, Boersma E, Westerhout CM, van Domburg R, Klein J, Bax JJ, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. American Journal of Medicine 2004;116(2):96-103.
58. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation 2010;121(7):e46-e215.
59. Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D, et al. AtheroGene Investigators. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arteriosclerosis, Thrombosis, and Vascular Biology 2006;26(12):2793-9.
60. Ohrlander T, Dencker M, Dias NV, Gottsäter A, Acosta S. Cardiovascular predictors for long-term mortality after EVAR for AAA. Vascular Medicine 2011;16(6):422-7.
61. Paravastu SCV, Jayarajasingam R, Cottam R, Palfreyman SJ, Michaels JA, Thomas SM. Endovascular repair of abdominal aortic aneurysm. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD004178.pub2]
62. Parr A, McCann M, Bradshaw B, Shahzad A, Buttner P, Golledge J. Thrombus volume is associated with cardiovascular events and aneurysm growth in patients who have abdominal aortic aneurysms. Journal of Vascular Surgery 2011;53(1):28-35.
63. Parry DJ, Al-Barjas HS, Chappell L, Rashid T, Ariëns RA, Scott DJ. Haemostatic and fibrinolytic factors in men with a small abdominal aortic aneurysm. British Journal of Surgery 2009;96(8):870-7.
64. Pleumeekers HJCM, Hoes AW, van der Does E, van Urk H, Hofman A, de Jong PTVM, et al. Aneurysms of the abdominal aorta in older adults. The Rotterdam Study. American Journal of Epidemiology 1995;142(12):1291-9 .
65. Prinssen M, Verhoeven ELG, Buth J, Cuypers PWM, van Sambeek MR, Balm R, et al. for the Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. New England Journal of Medicine 2004;351(16):1607-18.
66. Nordic Cochrane Centre, the Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, the Cochrane Collaboration, 2014.
67. Rughani G, Robertson L, Clarke M. Medical treatment for small abdominal aortic aneurysms. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD009536.pub2]
68. Schouten O, Kok NF, Hoedt MT, van Laanen JH, Poldermans D. The influence of aneurysm size on perioperative cardiac outcome in elective open infrarenal aortic aneurysm repair. Journal of Vascular Surgery 2006;44(3):435-41.
69. Scott RA, Bridgewater SG, Ashton HA. Randomized clinical trial of screening for abdominal aortic aneurysm in women. British Journal of Surgery 2002;89(3):283-5.
70. Singh K, Bønaa KH, Jacobsen BK, Bjørk L, Solberg S. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study. The Tromsø Study. American Journal of Epidemiology 2001;154(3):236-44.
71. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Schlomo Y, Lowe G. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly study. Circulation 2005;112(20):3080-7.
72. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
73. Takagi H, Manabe H, Kawai N, Goto S, Umemoto T. Plasma fibrinogen and D-dimer concentrations are associated with the presence of abdominal aortic aneurysm: a systematic review and meta-analysis. European Journal of Vascular and Endovascular Surgery 2009;38(3):273-7.
74. Timmers TK, van Herwaarden JA, de Borst GJ, Moll FL, Leenen LP. Long-term survival and quality of life after open abdominal aortic aneurysm repair. World Journal of Surgery 2013;37(12):2957-6.
75. van Vlijmen-van Keulen CJ, Pals G, Rauwerda JA Familial abdominal aortic aneurysm: a systematic review of a genetic background. European Journal of Vascular and Endovascular Surgery 2002;24(2):105-16.
76. Wanhainen A. How to define an abdominal aortic aneurysm--influence on epidemiology and clinical practice. Scandinavian Journal of Surgery 2008;97(2):105-9, discussion 109.
77. Wilmink TB, Quick CR, Day NE. The association between cigarette smoking and abdominal aortic aneurysms. Journal of Vascular Surgery 1999;30(6):1099-105.
78. Robertson L, Atallah E, Stansby G. Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD010447]
79. Robertson L, Atallah E, Stansby G. Pharmacological treatment of vascular risk factors for reducing mortality and cardiovascular events in patients with abdominal aortic aneurysm. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD010447.pub2]